Alemtuzumab.
Publication
, Journal Article
Weaver, TA; Kirk, AD
Published in: Transplantation
December 27, 2007
Alemtuzumab is a humanized CD52-specific monoclonal antibody that is increasingly used off-label as an induction agent in solid organ transplantation, particularly in the setting of maintenance immunosuppression minimization protocols. In this review, we briefly discuss this agent's mechanisms of action and summarize evidence supporting its use in this clinical setting.
Duke Scholars
Published In
Transplantation
DOI
ISSN
0041-1337
Publication Date
December 27, 2007
Volume
84
Issue
12
Start / End Page
1545 / 1547
Location
United States
Related Subject Headings
- Transplantation Immunology
- Surgery
- Immunosuppressive Agents
- Humans
- Clinical Trials as Topic
- Antibodies, Neoplasm
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Alemtuzumab
- 3204 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Weaver, T. A., & Kirk, A. D. (2007). Alemtuzumab. Transplantation, 84(12), 1545–1547. https://doi.org/10.1097/01.tp.0000296680.75175.67
Weaver, Timothy A., and Allan D. Kirk. “Alemtuzumab.” Transplantation 84, no. 12 (December 27, 2007): 1545–47. https://doi.org/10.1097/01.tp.0000296680.75175.67.
Weaver TA, Kirk AD. Alemtuzumab. Transplantation. 2007 Dec 27;84(12):1545–7.
Weaver, Timothy A., and Allan D. Kirk. “Alemtuzumab.” Transplantation, vol. 84, no. 12, Dec. 2007, pp. 1545–47. Pubmed, doi:10.1097/01.tp.0000296680.75175.67.
Weaver TA, Kirk AD. Alemtuzumab. Transplantation. 2007 Dec 27;84(12):1545–1547.
Published In
Transplantation
DOI
ISSN
0041-1337
Publication Date
December 27, 2007
Volume
84
Issue
12
Start / End Page
1545 / 1547
Location
United States
Related Subject Headings
- Transplantation Immunology
- Surgery
- Immunosuppressive Agents
- Humans
- Clinical Trials as Topic
- Antibodies, Neoplasm
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Alemtuzumab
- 3204 Immunology